London—Dentons has advised RoslinCT, a leader in advanced cell therapies contract development and manufacturing, on Global Healthcare Opportunities (GHO) Capital Partners' investment into the company.

Edinburgh-based RoslinCT was established in 2006 with support from Scottish Enterprise. It was formed through an initial spin-out from the Roslin Institute, which has a famous track record in genetic and cellular biology. Since 2014, the company has had a manufacturing base within the University of Edinburgh’s Centre for Regenerative Medicine. RoslinCT has worked to advance the field of regenerative medicine and is currently at the forefront of high-quality cell therapy development and manufacturing.

With the backing of GHO, a specialist investor in global healthcare, the company will significantly increase its development and manufacturing capacity, scaling the business up to build on its best-in-class therapies and better service a growing international client base.

RoslinCT CEO Janet Downie said, 'The Dentons team provided excellent support to us throughout the transaction process and we are grateful for their expertise and professionalism in helping us with this transformational investment.

The Dentons team was led by Head of UK Corporate Brian Moore, supported by Senior Associate Adam Knowles, TMT Partner Ross Nicol and Tax Partner Lorna McCaa.

Brian said, 'It's been a pleasure supporting such a highly skilled team in delivering this game-changing investment. The company is a real Scottish success story and has made huge advancements in life-changing cell therapies.  We look forward to supporting RoslinCT on the next stage of its growth.'

Slaughter and May acted as legal advisor to GHO.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com